Merial Announces Avian Site Closure
US - Merial announced that it has made the decision to close the Berlin, Maryland, Avian manufacturing site and transfer the production activities of Avian vaccines into other Merial manufacturing sites in the US.The transfer of vaccine production activities will occur over the coming two years with operations in Berlin anticipated to end in mid-2014. The site currently employs approximately 45 employees.
Merial's Avian business continues to remain strong and this decision does not affect Merial's commitment to its Avian customers. This strategic decision is being taken to reduce the manufacturing site network complexity and utilise the capabilities of the existing plants more efficiently.
Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,600 people and operates in more than 150 countries worldwide. Its 2011 sales were more than $2.8 billion.
Merial is a Sanofi company.